Artificial intelligence in hematology

Artificial intelligence (AI) and its subdiscipline, machine learning (ML), have the potential to revolutionize health care, including hematology. The diagnosis and treatment of hematologic disorders depend on the integration of diverse data sources, such as imaging, pathology, omics, and laboratory parameters. The increasing volume and complexity of patient data have made clinical decision-making more challenging. AI/ML hold significant potential for enhancing diagnostic accuracy, risk stratification, and treatment response prediction through advanced modeling techniques. Generative AI, a recent advancement within the broader field of AI, is poised to have a profound impact on health care and hematology. Generative AI can enhance the development of novel therapeutic strategies, improve diagnostic workflows by generating high-fidelity images or pathology reports, and facilitate more personalized approaches to patient management. Its ability to augment clinical decision-making and streamline research represents a significant leap forward in the field. However, despite this potential, few AI/ML tools have been fully implemented in clinical practice due to challenges related to data quality, equity, advanced infrastructure, and the establishment of robust evaluation metrics. Despite its promise, AI implementation in hematology faces critical challenges, including bias, data quality issues, and a lack of regulatory frameworks and safety standards that keep pace with rapid technological advancements. In this review, we provide an overview of the current state of AI/ML in hematology as of 2025, identify existing gaps, and offer insights into future developments.

Authors

Institutions

Publication Details

Journal
Blood
Published
2025-08-22
DOI
https://doi.org/10.1182/blood.2025029876
Citations
9
Primary Topic
AI in cancer detection
Type
article
Field-Weighted Citation Impact
22.33

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Artificial intelligence in hematology

Barbara D. Lam, Sanjay Ahuja, Roni Shouval, Olivier Elemento et al.
9 citations
Blood
AI in cancer detection
22.33
article

Artificial intelligence in hematology

Barbara D. Lam, Sanjay Ahuja, Roni Shouval, Olivier Elemento, Shannon K. McWeeney, Shireen Sirhan, Moses E. Miles, Aziz Nazha, Andrew Srisuwananukorn, Torsten Haferlach
article en
9 citations

Abstract

Artificial intelligence (AI) and its subdiscipline, machine learning (ML), have the potential to revolutionize health care, including hematology. The diagnosis and treatment of hematologic disorders depend on the integration of diverse data sources, such as imaging, pathology, omics, and laboratory parameters. The increasing volume and complexity of patient data have made clinical decision-making more challenging. AI/ML hold significant potential for enhancing diagnostic accuracy, risk stratification, and treatment response prediction through advanced modeling techniques. Generative AI, a recent advancement within the broader field of AI, is poised to have a profound impact on health care and hematology. Generative AI can enhance the development of novel therapeutic strategies, improve diagnostic workflows by generating high-fidelity images or pathology reports, and facilitate more personalized approaches to patient management. Its ability to augment clinical decision-making and streamline research represents a significant leap forward in the field. However, despite this potential, few AI/ML tools have been fully implemented in clinical practice due to challenges related to data quality, equity, advanced infrastructure, and the establishment of robust evaluation metrics. Despite its promise, AI implementation in hematology faces critical challenges, including bias, data quality issues, and a lack of regulatory frameworks and safety standards that keep pace with rapid technological advancements. In this review, we provide an overview of the current state of AI/ML in hematology as of 2025, identify existing gaps, and offer insights into future developments.

BloodVol. 146(19)
Memorial Sloan Kettering Cancer Center (US), Thomas Jefferson University (US), Oregon Health & Science University (US), Cornell University (US), Jewish General Hospital (CA), Lander Institute (IL), Fred Hutch Cancer Center (US), Munich Leukemia Laboratory (Germany) (DE), Sidney Kimmel Cancer Center (US), Innovative Clinical Research (US), Jefferson University Hospitals (US), American Thrombosis and Hemostasis Network (US), Indiana Hemophilia and Thrombosis Center (US), McGill University (CA), The Ohio State University (US)
AstraZeneca, Sanofi, CSL Behring, Incyte, Novo Nordisk, Swedish Orphan Biovitrum, National Institutes of Health, U.S. Food and Drug Administration, Genentech, National Cancer Institute
Industry, innovation and infrastructure
Openalex Percentile: Top 1%
AI in cancer detection
22.33
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.